Characteristics of molecular classification in 52 endometrial cancer and atypical hyperplasia patients receiving fertility-sparing treatment

Q4 Medicine
Yiqin Wang , Nan Kang , Liwei Li , Zhiqi Wang , Rong Zhou , Danhua Shen , Jianliu Wang
{"title":"Characteristics of molecular classification in 52 endometrial cancer and atypical hyperplasia patients receiving fertility-sparing treatment","authors":"Yiqin Wang ,&nbsp;Nan Kang ,&nbsp;Liwei Li ,&nbsp;Zhiqi Wang ,&nbsp;Rong Zhou ,&nbsp;Danhua Shen ,&nbsp;Jianliu Wang","doi":"10.1016/j.gocm.2023.01.006","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><p>To investigate the molecular classification of endometrial cancer (EC) and atypical endometrial hyperplasia (AEH) patients treated with fertility-sparing treatment (FST), and its relationship with clinicopathological factors and treatment efficacy. Methods: A total of 52 ​EC and AEH patients who received FST and molecular classification tested by next generation sequencing in Peking University People's Hospital from June 2020 to December 2022, were retrospectively collected. We analyzed the relationship between molecular classification and clinicopathological factors and treatment outcomes.</p></div><div><h3>Results</h3><p>(1) Of the 52 patients, including 46 ​EC and 6 AEH patients, 42 (80.8%) achieved complete remission (CR) after FST, with a median time to achieve CR of 9 months. Ten cases (23.8%) had recurrence. (2) Patients were distributed into 4 molecular subgroups as 39 cases (75%) of copy number low (CNL) , 7 cases (13.5%) of microsatellite instability-high (MSI-H) , 4 cases (7.7%) of POLE mutations (POLEmut), and 2 cases (3.8%) of copy number high (CNH). Patients with MSI-H subgroup had more family history of tumor (6/7), more with loss of expression of mismatch repair (MMR) protein (7/7), and higher expression level of Ki-67 (3/3). (3) Patients with MSI-H subgroup had the lowest CR rate at 6 months (0/7, P ​= ​0.014), and survival analysis showed that such patients were less likely to achieve CR than those with CNL (P ​= ​0.022). For CNL patients, median 6-month CR rate was 40.6%. In addition, CR was obtained in 3 (3/4) POLEmut patients and 2 (2/2) CNH patients, respectively.</p></div><div><h3>Conclusions</h3><p>Molecular classification relates with the treatment response in patients with EC and AEH receiving FST. Patients with MSI-H subgroup have poor treatment efficacy, and patients with CNL need to be further divided to predict treatment benefit. There are also a few successful cases in POLEmut and CNH subtgroups, which needs further research.</p></div>","PeriodicalId":34826,"journal":{"name":"Gynecology and Obstetrics Clinical Medicine","volume":"3 1","pages":"Pages 38-43"},"PeriodicalIF":0.0000,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gynecology and Obstetrics Clinical Medicine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2667164623000064","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Objective

To investigate the molecular classification of endometrial cancer (EC) and atypical endometrial hyperplasia (AEH) patients treated with fertility-sparing treatment (FST), and its relationship with clinicopathological factors and treatment efficacy. Methods: A total of 52 ​EC and AEH patients who received FST and molecular classification tested by next generation sequencing in Peking University People's Hospital from June 2020 to December 2022, were retrospectively collected. We analyzed the relationship between molecular classification and clinicopathological factors and treatment outcomes.

Results

(1) Of the 52 patients, including 46 ​EC and 6 AEH patients, 42 (80.8%) achieved complete remission (CR) after FST, with a median time to achieve CR of 9 months. Ten cases (23.8%) had recurrence. (2) Patients were distributed into 4 molecular subgroups as 39 cases (75%) of copy number low (CNL) , 7 cases (13.5%) of microsatellite instability-high (MSI-H) , 4 cases (7.7%) of POLE mutations (POLEmut), and 2 cases (3.8%) of copy number high (CNH). Patients with MSI-H subgroup had more family history of tumor (6/7), more with loss of expression of mismatch repair (MMR) protein (7/7), and higher expression level of Ki-67 (3/3). (3) Patients with MSI-H subgroup had the lowest CR rate at 6 months (0/7, P ​= ​0.014), and survival analysis showed that such patients were less likely to achieve CR than those with CNL (P ​= ​0.022). For CNL patients, median 6-month CR rate was 40.6%. In addition, CR was obtained in 3 (3/4) POLEmut patients and 2 (2/2) CNH patients, respectively.

Conclusions

Molecular classification relates with the treatment response in patients with EC and AEH receiving FST. Patients with MSI-H subgroup have poor treatment efficacy, and patients with CNL need to be further divided to predict treatment benefit. There are also a few successful cases in POLEmut and CNH subtgroups, which needs further research.

52例癌症和不典型增生患者保留受精治疗的分子分类特征
目的探讨保留生育治疗(FST)对子宫内膜癌(EC)和非典型子宫内膜增生(AEH)患者的分子分型及其与临床病理因素和治疗效果的关系。方法:回顾性收集2020年6月至2022年12月北京大学人民医院接受FST和下一代测序分子分型检测的EC和AEH患者52例。结果(1)52例患者中,46例EC, 6例AEH, 42例(80.8%)在FST后达到完全缓解(CR),中位达到CR的时间为9个月。复发10例(23.8%)。(2)低拷贝数(CNL)患者39例(75%),微卫星不稳定-高拷贝数(MSI-H)患者7例(13.5%),极突变(POLEmut)患者4例(7.7%),高拷贝数(CNH)患者2例(3.8%)。MSI-H亚组患者肿瘤家族史较多(6/7),错配修复(MMR)蛋白表达缺失较多(7/7),Ki-67表达水平较高(3/3)。(3) MSI-H亚组患者在6个月时的CR率最低(0/7,P = 0.014),生存分析显示MSI-H亚组患者实现CR的可能性低于CNL患者(P = 0.022)。CNL患者6个月的中位CR率为40.6%。此外,3(3/4)例POLEmut患者和2(2/2)例CNH患者分别获得了CR。结论分子分型与接受FST治疗的EC和AEH患者的治疗反应有关。MSI-H亚组患者治疗效果较差,CNL患者需要进一步划分以预测治疗效果。在POLEmut和CNH亚群中也有一些成功的案例,需要进一步的研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Gynecology and Obstetrics Clinical Medicine
Gynecology and Obstetrics Clinical Medicine Medicine-Obstetrics and Gynecology
CiteScore
0.70
自引率
0.00%
发文量
35
审稿时长
18 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信